Cargando…

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia

Aberrant signaling triggered by oncogenic or hyperactive RAS proteins contributes to the malignant phenotypes in a significant percentage of myeloid malignancies. Of these, juvenile myelomonocytic leukemia (JMML), an aggressive childhood cancer, is largely driven by mutations in RAS genes and those...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, Stacey J., Cosenza, Stephen C., Ramana Reddy, M.V., Premkumar Reddy, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443005/ https://www.ncbi.nlm.nih.gov/pubmed/30956775 http://dx.doi.org/10.18632/oncotarget.26735

Ejemplares similares

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia
por: Padgaonkar, Amol, et al.
Publicado: (2018)

Dual Inhibition of CDK4/Rb and PI3K/AKT/mTOR Pathways by ON123300 Induces Synthetic Lethality in Mantle Cell Lymphomas
por: Divakar, Saikrishna A., et al.
Publicado: (2015)

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair
por: Malacrida, Alessio, et al.
Publicado: (2021)

ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines
por: Prasad, Anil, et al.
Publicado: (2016)

ON01210.Na (Ex-RAD(®)) Mitigates Radiation Damage through Activation of the AKT Pathway
por: Kang, Anthony D., et al.
Publicado: (2013)

Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2020)

Anti-tumor effects of rigosertib in high-risk neuroblastoma
por: Radke, Katarzyna, et al.
Publicado: (2021)

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent
por: Malacrida, Alessio, et al.
Publicado: (2023)

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome
por: Xu, Feng, et al.
Publicado: (2014)

The Role of MicroRNAs in Myeloproliferative Neoplasia
por: Alizadeh, Shaban, et al.
Publicado: (2016)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Hematopoietic Neoplasias in Horses: Myeloproliferative and Lymphoproliferative Disorders
por: MUÑOZ, Ana, et al.
Publicado: (2010)

VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia
por: Austestad, Janne, et al.
Publicado: (2023)

NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease
por: Aydin, Ebru, et al.
Publicado: (2018)

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)
por: Monfort-Vengut, Ana, et al.
Publicado: (2023)

Rigosertib inhibits MEK1–ERK pathway and alleviates lipopolysaccharide‐induced sepsis
por: Wang, Yin, et al.
Publicado: (2021)

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells
por: Malacrida, Alessio, et al.
Publicado: (2021)

Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia
por: Holst, Johanne Marie, et al.
Publicado: (2021)

Interstitial Granulomatous Dermatitis due to a Rare Myeloproliferative Neoplasia
por: Cases-Merida, Sandra, et al.
Publicado: (2018)

Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
por: Rawat, Vipin, et al.
Publicado: (2023)

Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease
por: Sato, Katsutoshi, et al.
Publicado: (2021)

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
por: Kim, Dongsung, et al.
Publicado: (2023)

Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib
por: Tang, Lin, et al.
Publicado: (2021)

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
por: Naramura, Mayumi, et al.
Publicado: (2011)

Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)
por: Reddy, M. V. Ramana, et al.
Publicado: (2014)

Blastoid mantle cell lymphoma in a patient with chronic myeloproliferative neoplasia
por: Soares, Thamiris Silva, et al.
Publicado: (2023)

Centrosome-Kinase Fusions Promote Oncogenic Signaling and Disrupt Centrosome Function in Myeloproliferative Neoplasms
por: Lee, Joanna Y., et al.
Publicado: (2014)

Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
por: Marcus, Rebecca, et al.
Publicado: (2021)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
por: Kang, R, et al.
Publicado: (2014)

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
por: Tape, Christopher J., et al.
Publicado: (2016)

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
por: Tape, Christopher J., et al.
Publicado: (2016)

Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
por: Learte-Aymamí, Soraya, et al.
Publicado: (2022)

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2017)

Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation
por: Günther, Julia K., et al.
Publicado: (2020)

Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis
por: Le Roux, Özgün, et al.
Publicado: (2022)

Immune modulatory effects of oncogenic KRAS in cancer
por: Hamarsheh, Shaima’a, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q1p4fmjkcpitqaqa68tn2d8700